Virpax Pharmaceuticals, Inc. (VRPX) Cash Flow Statement
Where VRPX’s cash came from and went, 2024
December 31, 2024 · U.S. dollars- Cash from operations
- −$16.71B
- Capital expenditures
- $0
- Free cash flow
- −$16.71B
- Returned to shareholders
- —
- Change in cash
- −$7.63B cash at year-end $1.51B
Drawn to scale: where the cash came from and how it was used. Hover for values.
VRPX operating cash flow, capex and free cash flow
VRPX cash flow trends, 2018–2024
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$1.8M2018 | −$16.71B2024 | — | |
| Capital expenditures | $02018 | $02024 | — | |
| Free cash flow | −$1.8M2018 | −$16.71B2024 | — | |
| Stock-based compensation | $384,9552018 | $134.7M2024 | +165.5%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
VRPX cash flow by activity
VRPX net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
VRPX cash flow statement
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Operating activities | |||||||
| Net income | −$12.1M | −$15.2M | −$21.7M | −$12.1M | −$4.3M | −$3.3M | −$2.6M |
| Depreciation & amortization | $12.9M | — | $18.3M | $12.0M | $4.2M | $3.2M | $2.6M |
| Stock-based compensation | $134.7M | $544,770 | $745,034 | $974,234 | $1.5M | $678,146 | $384,955 |
| Change in working capital | −$4.8M | $4.8M | $3.1M | −$3.4M | $1.3M | $931,889 | $441,371 |
| Other non-cash items | −$16.84B | $0 | −$18.3M | −$12.1M | −$4.0M | −$2.6M | −$2.6M |
| Cash from operating activities | −$16.71B | −$9.9M | −$17.8M | −$14.5M | −$1.4M | −$1.1M | −$1.8M |
| Investing activities | |||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing activities | |||||||
| Net borrowing (repayment) | — | — | $0 | −$1.5M | $72,100 | $500,000 | $554,766 |
| Shares issued | $6.3M | $0 | $0 | $58.0M | $1.4M | $625,000 | $1.1M |
| Other financing | $9.08B | $0 | $50,880 | −$5.2M | −$50,880 | $0 | $0 |
| Cash from financing activities | $9.08B | $0 | $50,880 | $51.3M | $1.4M | $1.1M | $1.7M |
| Summary | |||||||
| Net change in cash | −$7.63B | −$9.9M | −$17.8M | $36.8M | $13,260 | −$6,834 | −$124,870 |
| Cash at end of period | $1.51B | $9.1M | $19.0M | $36.8M | $54,796 | $41,536 | $48,370 |
| Free cash flow | −$16.71B | −$9.9M | −$17.8M | −$14.5M | −$1.4M | −$1.1M | −$1.8M |
| Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$3.4M | −$2.0M | −$3.5M | −$3.2M | −$4.6M | −$6.0M | −$3.1M | −$1.5M | −$3.0M | −$7.6M | −$5.9M | −$5.1M |
| Depreciation & amortization | — | $1.9M | $3.5M | $3.3M | $918,099 | $6.1M | $3.2M | $2.9M | $1.1M | $7.7M | $5.9M | $5.1M |
| Stock-based compensation | $7,200 | −$17,730 | $72,510 | $72,719 | −$9,634 | $195,564 | $218,257 | $140,583 | $138,276 | $150,717 | $244,701 | $211,340 |
| Change in working capital | $512,201 | −$2.4M | $1.7M | −$4.6M | $1.6M | $3.1M | $711,593 | −$628,416 | $1.3M | $2.0M | $904,014 | −$1.1M |
| Other non-cash items | $0 | −$1.9M | −$3.5M | −$3.3M | −$918,099 | −$6.1M | −$3.2M | −$2.9M | −$1.1M | −$7.7M | −$5.9M | −$5.1M |
| Cash from operating activities | −$2.9M | −$4.5M | −$1.6M | −$7.7M | −$3.0M | −$2.7M | −$2.2M | −$2.0M | −$1.6M | −$5.5M | −$4.7M | −$6.0M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | −$3 | −$3 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing activities | ||||||||||||
| Shares issued | $4.1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $299,210 | $2.6M | $1.6M | $453,951 | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash from financing activities | $4.4M | $2.6M | $1.6M | $453,951 | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Summary | ||||||||||||
| Net change in cash | $1.5M | −$1.9M | $4,598 | −$7.3M | −$3.0M | −$2.7M | −$2.2M | −$2.0M | −$1.6M | −$5.5M | −$4.7M | −$6.0M |
| Cash at end of period | $1.5M | $17,229 | $1.9M | $1.9M | $9.1M | $12.2M | $14.8M | $17.0M | $19.0M | $20.6M | $26.1M | $30.8M |
| Free cash flow | −$2.9M | −$4.5M | −$1.6M | −$7.7M | −$3.0M | −$2.7M | −$2.2M | −$2.0M | −$1.6M | −$5.5M | −$4.7M | −$6.0M |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
VRPX cash generation
In fiscal 2024 (ended December 31, 2024), Virpax Pharmaceuticals generated -$16.7 billion of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$16.7 billion. Cash and equivalents fell by $7.6 billion over the year.
Related: VRPX income statement, VRPX balance sheet. See the VRPX stock overview for the latest quote and news.
VRPX cash flow FAQ
What is Virpax Pharmaceuticals's free cash flow?
Virpax Pharmaceuticals's free cash flow was -$16.7 billion in fiscal 2024: -$16.7 billion of operating cash flow minus $0 of capital expenditures It was -$9.9 million a year earlier..
How much cash does Virpax Pharmaceuticals generate from operations?
Virpax Pharmaceuticals generated -$16.7 billion of cash from operating activities in fiscal 2024.